GlassScriptPhysician profile
Kathleen Carpio
NPI 1538694963
$6,750.63
in general payments reported to CMS, 2019-2025
43 companies · $2,465 in 2025
The $2,465 reported for 2025 was more than what 96% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $258 · 2021: $531 · 2022: $519 · 2023: $933 · 2024: $2,044 · 2025: $2,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270 · Long Term Medical Supply Or Device Loan: $130 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.53 |
| Long Term Medical Supply Or Device Loan | $129.96 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,147.56 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $706.04 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $651.05 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $582.58 | 2022-2025 | Qulipta |
| Exact Sciences Corporation | $444.45 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $395.85 | 2022-2025 | |
| Abbott Laboratories | $384.63 | 2021-2025 | Freestyle Copilot, Freestyle Libre 3, Proclaim |
| Corcept Therapeutics | $345.84 | 2024-2025 | Korlym |
| Lilly USA, LLC | $266.88 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Insulet Corporation | $240.87 | 2025 | Omnipod, Omnipod |
| Glaxosmithkline, LLC. | $194.94 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Qol Medical, LLC | $125.00 | 2024 | Sucraid |
| Xeris Pharmaceuticals, INC. | $102.75 | 2024-2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $94.01 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Pfizer INC. | $92.20 | 2023-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Carpio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.